by Clinical Neuropsychologist | Thursday, August 8, 2024 | Dementia
Abstract INTRODUCTION Whether plasma biomarkers play roles in predicting incident dementia among the general population is worth exploring. METHODS A total of 1857 baseline dementia-free older adults with follow-ups up to 13.5 years were included from a...
by Clinical Neuropsychologist | Thursday, August 8, 2024 | Dementia
Abstract INTRODUCTION Relationships and interplay of an infection burden (IB) and periodontal pathogens or periodontal disease (Pd) markers with Alzheimer’s disease (AD) and all-cause dementia among US adults were examined. METHODS Less than or equal to 2997...
by Clinical Neuropsychologist | Thursday, August 8, 2024 | Dementia
Abstract INTRODUCTION Whether brain functional connectivity (FC) is consistently disrupted in individuals with mild cognitive impairment (MCI) with isolated language impairment (ilMCI), and its potential to differentiate between MCI subtypes remains uncertain. METHODS...
by Clinical Neuropsychologist | Wednesday, August 7, 2024 | Dementia
Abstract BACKGROUND Subjective cognitive decline (SCD) has been recognized as a potential risk stage for progression to Alzheimer’s disease (AD), while glymphatic dysfunction is considered an important characteristic of AD. We hypothesize that glymphatic...
by Clinical Neuropsychologist | Wednesday, August 7, 2024 | Dementia
Abstract The Alzheimer’s Disease Neuroimaging Initiative (ADNI) PET Core has evolved over time, beginning with positron emission tomography (PET) imaging of a subsample of participants with [18F]fluorodeoxyglucose (FDG)-PET, adding tracers for measurement of...
by Clinical Neuropsychologist | Tuesday, August 6, 2024 | Dementia
Abstract Recent approvals of amyloid immunotherapy drugs for early Alzheimer’s disease (AD) have been highly controversial. In this piece, we consider challenges from the clinical, population health, and health systems perspectives to the role that the new AD...
